Yun Zhong
Stock Analyst at Wedbush
(0.08)
# 4,841
Out of 5,133 analysts
472
Total ratings
37.6%
Success rate
-9.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterated: Buy | $327 → $346 | $275.39 | +25.64% | 34 | Nov 13, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $15 → $12 | $2.30 | +421.74% | 26 | Nov 13, 2026 | |
| KROS Keros Therapeutics | Reiterated: Hold | $16 | $10.30 | +55.34% | 17 | Nov 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $173 | $130.95 | +32.11% | 31 | Nov 9, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $8 | $1.73 | +362.43% | 26 | Nov 9, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | $8 | $3.80 | +110.53% | 11 | Nov 6, 2026 | |
| MNKD MannKind | Rated: Buy | $8 | $4.13 | +93.70% | 28 | Nov 6, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $3.66 | +64.16% | 27 | Nov 6, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $35 | $16.07 | +117.80% | 36 | Nov 6, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | $34 | $12.50 | +172.00% | 25 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.13 | +283.39% | 25 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $94 → $89 | $57.23 | +55.51% | 19 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $9.04 | +88.05% | 4 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $10.22 | +173.97% | 14 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $3.98 | +226.63% | 13 | Oct 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $17 | $1.58 | +979.37% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 | $4.25 | +88.24% | 24 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $28 | $0.9335 | n/a | 15 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.10 | n/a | 14 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 | $23.81 | n/a | 19 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $21.14 | n/a | 13 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.13 | n/a | 7 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.3075 | n/a | 9 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $6.35 | n/a | 13 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $91.81 | n/a | 9 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.87 | n/a | 3 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $13.15 | n/a | 2 | Feb 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $18.74 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $14.15 | n/a | 3 | Jun 28, 2018 |
Ascendis Pharma
Nov 13, 2026
Reiterated: Buy
Price Target: $327 → $346
Current: $275.39
Upside: +25.64%
Rocket Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $15 → $12
Current: $2.30
Upside: +421.74%
Keros Therapeutics
Nov 9, 2026
Reiterated: Hold
Price Target: $16
Current: $10.30
Upside: +55.34%
Protagonist Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $173
Current: $130.95
Upside: +32.11%
Voyager Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $8
Current: $1.73
Upside: +362.43%
Camp4 Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $8
Current: $3.80
Upside: +110.53%
MannKind
Nov 6, 2026
Rated: Buy
Price Target: $8
Current: $4.13
Upside: +93.70%
Rezolute
Nov 6, 2026
Reiterated: Buy
Price Target: $6
Current: $3.66
Upside: +64.16%
Sarepta Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $35
Current: $16.07
Upside: +117.80%
MoonLake Immunotherapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $34
Current: $12.50
Upside: +172.00%
Nov 4, 2026
Reiterated: Buy
Price Target: $12
Current: $3.13
Upside: +283.39%
Nov 3, 2026
Rated: Buy
Price Target: $94 → $89
Current: $57.23
Upside: +55.51%
Oct 28, 2026
Reiterated: Buy
Price Target: $17
Current: $9.04
Upside: +88.05%
Oct 22, 2026
Reiterated: Buy
Price Target: $28
Current: $10.22
Upside: +173.97%
Oct 19, 2026
Reiterated: Buy
Price Target: $13
Current: $3.98
Upside: +226.63%
Aug 11, 2026
Rated: Buy
Price Target: $17
Current: $1.58
Upside: +979.37%
Apr 21, 2026
Downgraded: Hold
Price Target: $8
Current: $4.25
Upside: +88.24%
Mar 30, 2023
Rated: Buy
Price Target: $28
Current: $0.9335
Upside: n/a
Mar 30, 2023
Reiterated: Hold
Price Target: n/a
Current: $4.10
Upside: n/a
Mar 28, 2023
Rated: Buy
Price Target: $38
Current: $23.81
Upside: n/a
Mar 23, 2023
Reiterated: Buy
Price Target: $4
Current: $21.14
Upside: n/a
Mar 21, 2023
Reiterated: Hold
Price Target: n/a
Current: $4.13
Upside: n/a
Mar 21, 2023
Reiterated: Buy
Price Target: $4
Current: $0.3075
Upside: n/a
Mar 21, 2023
Reiterated: Buy
Price Target: $8
Current: $6.35
Upside: n/a
Jan 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $91.81
Upside: n/a
May 12, 2020
Reiterated: Buy
Price Target: $10
Current: $0.87
Upside: n/a
Feb 4, 2020
Reiterated: Buy
Price Target: $14
Current: $13.15
Upside: n/a
Nov 12, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $18.74
Upside: n/a
Jun 28, 2018
Downgraded: Hold
Price Target: n/a
Current: $14.15
Upside: n/a